EUVIMEDEUVIMED entdecken
ÄquivalenzstudieMultizentrische StudieRandomisierte kontrollierte Studie

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

A Michael Lincoff iD, Kirstine Brown-Frandsen, Helen M Colhoun, John Deanfield, Scott S Emerson, Sille Esbjerg, Søren Hardt-Lindberg, G Kees Hovingh, Steven E Kahn, Robert F Kushner, Ildiko Lingvay iD, Tugce K Oral und 5 weitere

New England Journal of Medicine · 14.12.2023 · 389 (24) · 2221-2232

DOI: 10.1056/nejmoa2307563 ↗

Kurz gefasst

Äquivalenzstudie in der Zeitschrift New England Journal of Medicine, erschienen am 14.12.2023. Verfasst von A Michael Lincoff und 16 weiteren Autor:innen. Beteiligte Einrichtung: From the Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cle…. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Obesity, Cardiovascular Agents. Die Arbeit wurde bisher 3373-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Novo Nordisk Pharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiovascular DiseasesObesityCardiovascular AgentsHumansDiabetes Mellitus, Type 2Double-Blind MethodGlucagon-Like PeptidesHypoglycemic AgentsMyocardial InfarctionOverweightStrokeGlucagon-Like Peptide-1 Receptor AgonistsSemaglutide

Substanzen

Glucagon-Like PeptidesHypoglycemic AgentsGlucagon-Like Peptide-1 Receptor AgonistsCardiovascular AgentsSemaglutide

Autor:innen und Institutionen

  • From the Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland (A.M.L.); Novo Nordisk, Søborg, Denmark (K.B.-F., S.E., S.H.-L.…

ORCID-Profile: A Michael Lincoff, Ildiko Lingvay

Förderung

  • Novo Nordisk Pharma

Zitieren

APA

Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., Lingvay, I., Oral, T. K., Michelsen, M. M., Plutzky, J., Tornøe, C. W., Ryan, D. H., & SELECT Trial Investigators (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine, 389(24), 2221-2232. https://doi.org/10.1056/nejmoa2307563

Vancouver

Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023;389(24):2221-2232. doi:10.1056/nejmoa2307563

BibTeX
@article{Lincoff2023,
  author = {Lincoff, A Michael and Brown-Frandsen, Kirstine and Colhoun, Helen M and Deanfield, John and Emerson, Scott S and Esbjerg, Sille and Hardt-Lindberg, Søren and Hovingh, G Kees and Kahn, Steven E and Kushner, Robert F and Lingvay, Ildiko and Oral, Tugce K and Michelsen, Marie M and Plutzky, Jorge and Tornøe, Christoffer W and Ryan, Donna H and SELECT Trial Investigators, SELECT Trial Investigators},
  title = {Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes},
  journal = {New England Journal of Medicine},
  year = {2023},
  volume = {389},
  number = {24},
  pages = {2221--2232},
  doi = {10.1056/nejmoa2307563}
}
Kostenlos starten →